An experimental antifungal called olorofim is giving fresh hope to patients with severe Valley Fever, especially those whose infections have spread from the lungs to the brain or spine. In a small clinical trial, the drug appeared to help most people who had already burned through the usual options, potentially reshaping what doctors try after azoles and amphotericin stop working.
A peer‑reviewed analysis in the Annals of Internal Medicine reports that a single‑arm phase 2b study of 41 patients produced adjudicated clinical success in roughly 76% of participants at day 42 and about 73% at day 84. The study focused on people with disseminated coccidioidomycosis who had limited or no options left with standard antifungal therapy.
How the trial worked
The trial, a multicenter open‑label study listed on ClinicalTrials.gov, enrolled patients between May 2019 and August 2022. Many participants had central‑nervous‑system disease, 30 of 41 in total, and 13 had ventriculoperitoneal shunts, details reported by the Los Angeles Times.
Why Californians should care
Valley Fever has surged in California in recent years. Provisional state data show more than 12,700 reported cases in 2024 and over 10,700 in 2025, with about 5,100 so far this year, making better treatments a pressing need, according to the California Department of Public Health. Clinicians on the study described olorofim as a potential salvage option for patients who fail standard therapy, and lead author Fariba Donovan said, "Olorofim actually kills the fungus," as quoted by the Los Angeles Times.
Safety, approvals and what's next
The trial reported liver‑enzyme elevations in about 22% of patients, most of which were handled with monitoring and dose adjustments, according to the Annals paper. Separately, manufacturers F2G and Shionogi released positive top‑line results from a phase 3 study of olorofim in invasive aspergillosis and said they plan regulatory submissions. The drug is not yet approved for Valley Fever, according to reporting from the American College of Physicians' news service. F2G and Newswise provide the ongoing regulatory context.
For now, olorofim looks like the most promising new option for a rare but devastating complication of Valley Fever. Experts say larger trials and full regulatory review will decide whether it graduates from experimental lifeline to standard tool for doctors treating Californians and others at risk.
